3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
OTHER
14
NIH
8
OTHER_GOV
1
NETWORK
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
114
Neoplasms
28
Lung Neoplasms
24
Non-Squamous Non-Small Cell Lung Cancer
21
Pancreatic Neoplasms
13
Colorectal Neoplasms
6
Neoplasm Metastasis
5
Breast Neoplasms
4
Respiratory Tract Neoplasms
3
Respiratory Tract Diseases
3
Lymphoma
3
Thoracic Neoplasms
2
Solid Tumors
2
Recurrence
2
Neoplasms by Site
2
Lung Diseases
2
Familial ependymoma
2
Ependymoma
2
Carcinoma, Renal Cell
2
Carcinoma, Hepatocellular
2
Carcinoma
2
Bronchial Neoplasms
2
Advanced Solid Tumors
2
Vascular Diseases
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor
1
Smoking
1
Small Cell Lung Carcinoma
1
Interventions
pembrolizumab
126
Cisplatin
47
Cetuximab
46
Nivolumab
36
Carboplatin
33
Paclitaxel
28
Fluorouracil
26
Docetaxel
17
avelumab
11
Radiotherapy
11
Cyclophosphamide
11
cemiplimab
10
atezolizumab
10
durvalumab
9
Ipilimumab
8
spartalizumab
7
budigalimab
7
Gemcitabine
7
Capecitabine
7
tremelimumab
6
lenvatinib
6
fludarabine
6
Pemetrexed
6
epacadostat
5
Fulvestrant
5
130-nm albumin-bound paclitaxel
5
zimberelimab
4
tislelizumab
4
Trastuzumab
4
Oxaliplatin
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Squamous Cell Carcinoma of Head and Neck
×
Erlotinib Hydrochloride
×
Clear all
NCT05827614
2026-01-23
POTENTIATE
Boundless Bio, Inc.
Phase 1
Active not recruiting
85 enrolled